Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $7.7 million.

  • Insight Molecular Diagnostics' Total Current Liabilities fell 1573.16% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 1573.16%. This contributed to the annual value of $7.3 million for FY2024, which is 112.59% up from last year.
  • Insight Molecular Diagnostics' Total Current Liabilities amounted to $7.7 million in Q3 2025, which was down 1573.16% from $6.7 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Total Current Liabilities high stood at $19.8 million for Q2 2021, and its period low was $6.7 million during Q2 2025.
  • In the last 5 years, Insight Molecular Diagnostics' Total Current Liabilities had a median value of $9.1 million in 2024 and averaged $10.3 million.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Total Current Liabilities soared by 18902.37% in 2021 and then plummeted by 4057.49% in 2023.
  • Insight Molecular Diagnostics' Total Current Liabilities (Quarter) stood at $14.1 million in 2021, then decreased by 14.26% to $12.1 million in 2022, then crashed by 40.57% to $7.2 million in 2023, then increased by 1.13% to $7.3 million in 2024, then rose by 5.29% to $7.7 million in 2025.
  • Its last three reported values are $7.7 million in Q3 2025, $6.7 million for Q2 2025, and $9.7 million during Q1 2025.